Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (7644)	5/6/1998 1:15:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 9262

[ angio chat ] Thread: Geeze, yesterday was an ugly "reality check" for RGEN. Too busy to breathe right now, but just wanted to make a brief comment. OSIP jumped yesterday when the angio craze spilled over into the quieter efforts (AGPH, etc.). One company that I didn't mention in the article for Microsoft Investor is OSIP. It is a quality, diversified play in genomics, with a sincere effort in angiogenesis. And, it has come back today (currently 7 1/4 "ask") as the momentum gang saw that it wasn't going to do an ENMD. Again, SUGN is also a diversified outfit with an advanced small molecule project in angio. And, finally...... of the "small molecule" efforts, I consider that of RGEN to be most like that of ENMD. ENMD is working with small hunks of proteins called peptides. Not good, from a cost and administration stand. RGEN is working with sulfated small organics. The mechanism of action for ENMD's molecules is not known, but I am working with the hypothesis that they block the action of certain growth factors that RGEN is also targeting. Very, very risky early-stage work, but they don't deserve, IMO, to have corrected yesterday to the same degree as some other efforts. So, here are my plays on angiogenesis (disclaimer.... I own them).... these are mine, do your homework and get your own....... OSIP SUGN and, much more speculative.... RGEN Ray: Maybe biotech is picking up. I'll be back later with my views of the discount pricing for good research, but my portfolio, mostly quality, long-term play stuff, is looking strong of late. Cheers! Rick